The Helin lab studies how fundamental biological processes are regulated and how these become perturbed in human disease, particularly in cancer. Our vision is that our research can play a role in developing new therapies for people with cancer and at the same time provide new insights into mechanisms regulating transcription, stem cell identity, and differentiation. Our research is focused on how chromatin-associated proteins regulate transcription and control cell-fate decisions. To do this we use a host of different methods in biochemistry, cell biology, and genetics (including mouse genetics) and a number of high-throughput genetic methods to identify potential novel therapeutic targets.
Kristian Helin, PhD
Chair, Cell Biology Program, SKI; Director, Center for Epigenetics
Research FocusCancer biologist Kristian Helin studies how genetic and epigenetic mechanisms affect transcription and cell-fate decisions, and how their deregulation contributes to cancer.
EducationPhD, University of Coepenhagen
- Højfeldt J, Laugesen A, Willumsen BM, Damhofer H, Hedehus L, Tvardovskiy A, Mohammad F, Jensen ON & Helin K. Accurate H3K27 methylation can be established de novo by SUZ12-directed PRC2. Nature Structural & Molecular Biology. (2018)
- Mohammad F, Weissmann S, Leblanc B, Pandey DP, Højfeldt, JW, Comet I, Zheng C, Johansen JV, Rapin N, Porse BT, Tvardovskiy A, Jensen ON, Olaciregui NG, Lavarino C, Suñol M, de Torres C, Mora J, Carcaboso AM & Helin K. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. Nature Medicine 4, 483-492, doi: 10.1038/nm.4293 (2017).
- Kirsten og Freddy Johansens pre-clinical Research Prize (2018)
- Director Ib Henriksen’s Foundation’s research prize (2015)
- The Anders Jahre Senior Medical Prize (2014)
- The Carlsberg Foundation’s Research Prize in Natural Sciences (2012)
- The innovation prize of University of Copenhagen (2011)